EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access · CC BY-NC 4.0

Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”

May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong

Clinical and Molecular Hepatology · 01.01.2026 · 32 (1) · 429-431

DOI: 10.3350/cmh.2025.0420 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.01.2026. Verfasst von May Xuan Goh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, Changi General Hospital, SingHealth Duke-NUS Academic Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

KoreaMetabolic dysfunction-associated steatohepatitisMetabolic dysfunction-associated steatotic liver diseaseReferral

Autor:innen und Institutionen

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Division of Gastroenterology & Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Department of Gastroenterology & Hepatology, Changi General Hospital, Singapore.
  • Duke-NUS Medical School, Singapore.

Förderung

  • NIDDK NIH HHS
  • Changi General Hospital
  • SingHealth Duke-NUS Academic Medical Center

Zitieren

APA

Goh, M. X., Goh, X. E., Tan, J. J., Chen, V. L., & Wong, Y. J. (2026). Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”. Clinical and Molecular Hepatology, 32(1), 429-431. https://doi.org/10.3350/cmh.2025.0420

Vancouver

Goh MX, Goh XE, Tan JJ, Chen VL, Wong YJ. Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”. Clinical and Molecular Hepatology. 2026;32(1):429-431. doi:10.3350/cmh.2025.0420

BibTeX
@article{Goh2026,
  author = {Goh, May Xuan and Goh, Xin En and Tan, Jarell Jie-Rae and Chen, Vincent L and Wong, Yu Jun},
  title = {Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {1},
  pages = {429--431},
  doi = {10.3350/cmh.2025.0420}
}
Kostenlos starten →